Therefore, it is not surprising that when seeking to target ERK5 in cancer (or other indications) there has been a lot of interest in developing small molecule inhibitors of the kinase domain, including our own collaborations with excellent drug discovery teams (Myers et al., 2019; Miller et al., 2022). Here, MAPK7 is linked to cancer.